Poetic Genetics

Poetic Genetics is a biotechnology company pioneering the development of programmable epigenome editing therapies. The company's core technology, the POETIC platform, enables the precise recruitment of chromatin regulators to specific genomic loci to modulate gene expression without altering the underlying DNA sequence. By targeting the epigenome rather than the genome itself, the company aims to provide durable therapeutic effects while avoiding the risks associated with double-stranded DNA breaks. Poetic Genetics is currently focused on advancing its platform for applications in rare genetic disorders, oncology, and neurodegeneration. The company is a spin-off from foundational research conducted at Stanford University.